SG11201908997UA - Compositions and methods for detecting prostate cancer - Google Patents
Compositions and methods for detecting prostate cancerInfo
- Publication number
- SG11201908997UA SG11201908997UA SG11201908997UA SG11201908997UA SG 11201908997U A SG11201908997U A SG 11201908997UA SG 11201908997U A SG11201908997U A SG 11201908997UA SG 11201908997U A SG11201908997U A SG 11201908997UA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- compositions
- methods
- rule
- prostate cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96402—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals
- G01N2333/96405—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals in general
- G01N2333/96408—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals in general with EC number
- G01N2333/96411—Serine endopeptidases (3.4.21)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Reproductive Health (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Abstract
WO 18/ 17 835 2 Al (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 04 October 2018 (04.10.2018) W I PO I PCT ill mu °mons I SID o VIII VIII imio VII IE (10) International Publication Number WO 2018/178352 Al (51) International Patent Classification: C07K 16/28 (2006.01) GO1N 33/574 (2006.01) C07K 16/30 (2006.01) A61K 39/00 (2006.01) (21) International Application Number: PCT/EP2018/058330 (22) International Filing Date: 30 March 2018 (30.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 17305381.0 30 March 2017 (30.03.2017) EP (71) Applicant: PROGASTRINE ET CANCERS S.A R.L. [LU/LU]; 11, C6te d'Eich, 1450 LUXEMBOURG (LU). (72) Inventor: PRIEUR, Alexandre; 24 me de la Cavalerie, 34000 MONTPELLIER (FR). (74) Agent: REGIMBEAU; 20, rue de Chazelles, 75847 PARIS CEDEX 17 (FR). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: of inventorship (Rule 4.17(iv)) Published: with international search report (Art. 21(3)) with (an) indication(s) in relation to deposited biological material furnished under Rule 13bis separately from the description (Rules 13bis.4(d)(i) and 48.2(a)(viii)) with sequence listing part of description (Rule 5.2(a)) (54) Title: COMPOSITIONS AND METHODS FOR DETECTING PROSTATE CANCER (57) : The present invention relates to compositions and methods for the in vitro diagnosis of prostate cancer, wherein said compositions comprise an antibody binding to progastrin and said methods comprise the use of an antibody binding to progastrin.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17305381 | 2017-03-30 | ||
PCT/EP2018/058330 WO2018178352A1 (en) | 2017-03-30 | 2018-03-30 | Compositions and methods for detecting prostate cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201908997UA true SG11201908997UA (en) | 2019-10-30 |
Family
ID=58501413
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201908998X SG11201908998XA (en) | 2017-03-30 | 2018-03-30 | Compositions and methods for detecting and treating prostate cancer using progastrin binding molecule |
SG11201908997U SG11201908997UA (en) | 2017-03-30 | 2018-03-30 | Compositions and methods for detecting prostate cancer |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201908998X SG11201908998XA (en) | 2017-03-30 | 2018-03-30 | Compositions and methods for detecting and treating prostate cancer using progastrin binding molecule |
Country Status (12)
Country | Link |
---|---|
US (2) | US11644468B2 (en) |
EP (2) | EP3601343B1 (en) |
JP (2) | JP7156622B2 (en) |
KR (2) | KR102317805B1 (en) |
CN (2) | CN110662769B (en) |
AU (2) | AU2018242152B2 (en) |
BR (2) | BR112019020414A2 (en) |
CA (2) | CA3058263C (en) |
EA (2) | EA201992318A1 (en) |
ES (2) | ES2904939T3 (en) |
SG (2) | SG11201908998XA (en) |
WO (2) | WO2018178352A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3720879B1 (en) * | 2017-12-05 | 2022-05-11 | Progastrine et Cancers S.à r.l. | Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer |
CA3085067A1 (en) | 2017-12-08 | 2019-06-13 | Ecs-Biotracker Sarl | Radiolabeled progastrin in cancer diagnosis |
TW201940881A (en) | 2018-01-26 | 2019-10-16 | 瑞士商Ecs前胃泌激素公司 | Combining progastrin detection with other cancer biomarkers in cancer diagnosis |
TW202000699A (en) | 2018-02-27 | 2020-01-01 | 瑞士商Ecs前胃泌激素公司 | Progastrin as a biomarker for immunotherapy |
CN111518908B (en) * | 2020-05-18 | 2023-10-17 | 奥尔文泰生物科技(杭州)有限公司 | Urine prostate cancer marker combination and application thereof in preparation of accurate diagnostic reagent |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
GB8924581D0 (en) | 1989-11-01 | 1989-12-20 | Pa Consulting Services | Bleaching of hair |
EP0463151B1 (en) | 1990-01-12 | 1996-06-12 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
DE69233482T2 (en) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Method for reducing the immunogenicity of antibody variable domains |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
JPH05244982A (en) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | Humanized b-b10 |
ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
ATE196606T1 (en) | 1992-11-13 | 2000-10-15 | Idec Pharma Corp | THERAPEUTIC USE OF CHIMERIC AND LABELED ANTIBODIES DIRECTED AGAINST A DIFFERENTIATION ANTIGEN WHICH EXPRESSION IS RESTRICTED TO HUMAN B LYMPHOCYTES, FOR THE TREATMENT OF B-CELL LYMPHOMA |
EP0708656B1 (en) * | 1993-04-27 | 2002-07-31 | United Biomedical, Inc. | Immunogenic lhrh peptide constructs and synthetic universal immune stimulators for vaccines |
CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
EP1500329B1 (en) | 1996-12-03 | 2012-03-21 | Amgen Fremont Inc. | Human antibodies that specifically bind human TNF alpha |
US7227002B1 (en) | 1997-04-14 | 2007-06-05 | Micromet Ag | Human antibodies that bind human 17-A1/EpCAM tumor antigen |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
WO1999018210A2 (en) * | 1997-10-07 | 1999-04-15 | Corixa Corporation | Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer |
AU783356B2 (en) * | 1999-07-29 | 2005-10-20 | Medarex, Inc. | Human monoclonal antibodies to prostate specific membrane antigen |
US20030232399A1 (en) | 2000-06-14 | 2003-12-18 | Robertson John Forsyth Russell | Cancer detection methods and reagents |
JP2003111595A (en) * | 2001-06-25 | 2003-04-15 | Kyogo Ito | Tumor antigen |
JP2003261460A (en) * | 2002-03-08 | 2003-09-16 | Kyowa Hakko Kogyo Co Ltd | Diagnostic agent and treating agent for lung selective cancer metastasis |
EP1391213A1 (en) | 2002-08-21 | 2004-02-25 | Boehringer Ingelheim International GmbH | Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents |
MXPA06014421A (en) * | 2004-06-10 | 2007-05-04 | Regeneron Pharma | Method of administering and using vegf inhibitors for the treatment of human cancer. |
JP2008513536A (en) * | 2004-09-22 | 2008-05-01 | レセプター バイオロジックス インコーポレイテッド | Monoclonal antibody against progastrin |
ATE511647T1 (en) * | 2005-04-13 | 2011-06-15 | Advanced Life Science Inst Inc | ANTIBODIES DIRECTED AGAINST GASTRIN RELEASING PEPTIDE PRECURSORS |
WO2011045080A2 (en) * | 2009-10-16 | 2011-04-21 | Biorealites S.A.S. | Monoclonal antibodies to progastrin and their uses |
US20130095503A1 (en) * | 2010-01-05 | 2013-04-18 | University Of Cincinnati | Serum spla2-iia as diagnosis marker for prostate and lung cancer |
US8900588B2 (en) * | 2010-01-08 | 2014-12-02 | Les Laboratories Servier | Methods for treating breast cancer |
US9217032B2 (en) * | 2010-01-08 | 2015-12-22 | Les Laboratoires Servier | Methods for treating colorectal cancer |
US8900817B2 (en) | 2010-01-08 | 2014-12-02 | Les Laboratories Servier | Progastrin and liver pathologies |
SG184092A1 (en) | 2010-03-24 | 2012-10-30 | Biorealites | Prophylaxis of colorectal and gastrointestinal cancer |
ES2871092T3 (en) | 2010-07-26 | 2021-10-28 | Progastrine Et Cancers S A R L | Methods and compositions for the therapy of liver cancer |
LT3071595T (en) | 2013-11-19 | 2019-05-10 | Fredax Ab | Humanised anti kallikrein-2 antibody |
WO2016066671A1 (en) * | 2014-10-29 | 2016-05-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for treating resistant cancers using progastrin inhibitors |
TW201639891A (en) * | 2015-03-10 | 2016-11-16 | 索倫多醫療公司 | Antibody therapeutics that bind PSMA |
KR102620651B1 (en) * | 2015-12-31 | 2024-01-04 | 신케레스 에스.에이 알.엘. | Compositions and methods for assessing the risk of developing cancer |
-
2018
- 2018-03-30 EA EA201992318A patent/EA201992318A1/en unknown
- 2018-03-30 EP EP18713967.0A patent/EP3601343B1/en active Active
- 2018-03-30 ES ES18714776T patent/ES2904939T3/en active Active
- 2018-03-30 KR KR1020197030346A patent/KR102317805B1/en active IP Right Grant
- 2018-03-30 WO PCT/EP2018/058330 patent/WO2018178352A1/en unknown
- 2018-03-30 SG SG11201908998X patent/SG11201908998XA/en unknown
- 2018-03-30 WO PCT/EP2018/058344 patent/WO2018178363A1/en unknown
- 2018-03-30 BR BR112019020414A patent/BR112019020414A2/en not_active Application Discontinuation
- 2018-03-30 ES ES18713967T patent/ES2921775T3/en active Active
- 2018-03-30 EA EA201992316A patent/EA201992316A1/en unknown
- 2018-03-30 CA CA3058263A patent/CA3058263C/en active Active
- 2018-03-30 AU AU2018242152A patent/AU2018242152B2/en active Active
- 2018-03-30 BR BR112019020413A patent/BR112019020413A2/en not_active IP Right Cessation
- 2018-03-30 US US16/498,557 patent/US11644468B2/en active Active
- 2018-03-30 JP JP2020503356A patent/JP7156622B2/en active Active
- 2018-03-30 CN CN201880034272.XA patent/CN110662769B/en active Active
- 2018-03-30 AU AU2018242156A patent/AU2018242156B2/en active Active
- 2018-03-30 SG SG11201908997U patent/SG11201908997UA/en unknown
- 2018-03-30 KR KR1020197031684A patent/KR102351556B1/en active IP Right Grant
- 2018-03-30 CA CA3058267A patent/CA3058267C/en active Active
- 2018-03-30 US US16/498,543 patent/US11614448B2/en active Active
- 2018-03-30 EP EP18714776.4A patent/EP3601347B1/en active Active
- 2018-03-30 JP JP2019553207A patent/JP7071994B2/en active Active
- 2018-03-30 CN CN201880034255.6A patent/CN110945025B/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201908997UA (en) | Compositions and methods for detecting prostate cancer | |
SG11201805263TA (en) | Compositions and methods for detecting and treating esophageal cancer | |
SG11201908996YA (en) | Compositions and methods for detecting lung cancer | |
SG11201407534PA (en) | New diazaspirocycloalkane and azaspirocycloalkane | |
SG11201908640TA (en) | Pyrrolidinones and a process to prepare them | |
SG11201805141QA (en) | Compositions and methods for detecting and treating gastric cancer | |
SG11201808108XA (en) | Synthesis of indazoles | |
SG11201901558VA (en) | Pth compounds with low peak-to-trough ratios | |
SG11201806485RA (en) | Pyrrolobenzodiazepine conjugates | |
SG11201908472VA (en) | Compositions and methods for activating nk cells | |
SG11201908325PA (en) | Process for the preparation of glucuronide drug-linkers and intermediates thereof | |
SG11201408224SA (en) | Novel ruthenium complexes, their use in the metathesis reactions, and a process for carrying out the metathesis reaction | |
SG11201900021PA (en) | Methods and compositions for the treatment of cancer | |
SG11201808686VA (en) | Synthesis of indazoles | |
SG11201907693VA (en) | Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof | |
SG11201906778RA (en) | Improved methods for assessing risk of developing breast cancer | |
SG11201901172QA (en) | A method for manufacturing a fuel component | |
SG11201907927SA (en) | Binding molecules that specifically bind to tau | |
SG11201805605TA (en) | Compositions and methods for detecting and treating ovarian cancer | |
SG11201908091QA (en) | Aqueous anti-pd-l1 antibody formulation | |
SG11201907208XA (en) | Radiolabeled anti-lag3 antibodies for immuno-pet imaging | |
SG11202000494UA (en) | Drug delivery composition | |
SG11201906313SA (en) | A polypeptide linker for preparing multispecific antibodies | |
SG11201803643TA (en) | Virulence attenuated bacteria for treatment of malignant solid tumors | |
SG11201804629XA (en) | Compositions and methods for assessing the risk of cancer occurrence |